agomab
The Director of Medical Writing leads narrative strategy and document quality across clinical programs, overseeing CRO medical writers and building scalable processes for pipeline progression into Phase 3. This hands-on leadership role combines document development with strategic cross-functional partnership to shape how documents communicate the program story and define medical writing standards, processes, and tools. The role also leads AI-assisted tools and workflows, establishing appropriate controls for human oversight, traceability, accuracy, confidentiality, validation, and quality.
Agomab Therapeutics (Nasdaq: AGMB) is a clinical-stage biopharmaceutical company focused on fibro-inflammation, developing growth factor-modulating therapies to treat fibrotic diseases. The company's pipeline includes Ontunisertib (AGMB-129), AGMB-447, and AGMB-101, with active clinical programs targeting conditions such as fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. Headquartered in Antwerp, Belgium, Agomab translates deep expertise in growth factor biology into disease-modifying treatments aimed at halting or reversing fibrosis and restoring organ function.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for agomab.
agomab didn’t post a salary, so this is our estimate from similar listings.
4% above the average for this role